Over-expression of human carcinoma-associated antigen in intrahepatic cholangiocellular carcinoma

Biochemical and Biophysical Research Communications

Volumn 405, Issue 2, 2011, Pages 325-332

  Zhou, Dong Xun ^a   Wang, Hao ^a   Zhou, HuaBang ^a   Li, Shuangxi ^a   Qu, Hai Xia ^a   Kou, XiaoXia ^a   Li, JingZe ^a   Wang, Hui ^a   Hu, He Ping ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cholangiocellular carcinoma; Clinical features; Human carcinoma associated antigen; Immunohistochemistry

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY; BCE075 ANTIBODY; BDD048 ANTIBODY; CA 19-9 ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; HEPATITIS B SURFACE ANTIGEN; HUMAN CARCINOMA ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CELL SECRETION; CELL STRUCTURE; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SATELLITE CELL; SPINDLE CELL; TUMOR CELL; TUMOR DIFFERENTIATION; TUMOR THROMBUS; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 79651474851     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.01.040     Document Type: Article

References (22)

1. Codington J.F., Bhavanandan V.P., Bloch K.J., et al. Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients. J. Natl. Cancer Inst. 1984, 73:1029-1038.
2. Bourne B.P., Yao J.L., Yang Q., Lei J., di Sant'Agnese P.A., Huang J. Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder. Arch. Pathol. Lab. Med. 2004, 128:785-787.
3. Yao J.L., Li R., Bourne P.A., di Sant'Agnese P.A., Huang J. Frequent expression of human carcinoma-associated antigen, a mucin-type glycoprotein, in cells of prostatic carcinoma. Arch. Pathol. Lab. Med. 2004, 128:1412-1417.
4. Liang S., Yao J., Bourne P.A., et al. Overexpression of human carcinoma-associated antigen in esophageal adenocarcinoma and its precursor lesions. Am. J. Clin. Pathol. 2004, 122:747-751.
5. Gebhart C.J., Guedes R.M., Deen J., Winkelman N.L. Validation of an immunoperoxidase monolayer assay as a serologic test for porcine proliferative enteropathy. J. Vet. Diagn. Invest. 2002, 14:528-530.
6. Guedes R.M., Gebhart C.J., Winkelman N.L., et al. A comparative study of an indirect fluorescent antibody test and an immunoperoxidase monolayer assay for the diagnosis of porcine proliferative enteropathy. J. Vet. Diagn. Invest. 2002, 14:420-423.
7. Kazmar R.E., Fathman C.G. Monoclonal antibodies: tools of the future. Mayo Clin. Proc. 1980, 55:517-518.
8. Thingstad T., Haavik S., Hansen K., et al. Human carcinoma-associated antigen (HCA), isolated from the endometrial carcinoma cell line KLE-1 and ascitic fluid of a patient with ovarian carcinoma; comparison with epiglycanin. Eur. J. Pharm. Sci. 1998, 6:121-129.
9. Daiss J.L., Carney J.L., Cartun R., et al. Human carcinoma antigen: a marker useful for discriminating between benign prostatic hyperplasia and prostate cancer. J. Clin. Ligand Assay 2003, 26:177-180.
10. Codington J.F., Haavik S., Nikrui N., et al. Immunologic quantitation of the carcinoma specific human carcinoma antigen in clinical samples. Cancer 2002, 94:803-813.
11. Blechacz B., Gores G.J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008, 48:308-321.
12. de Groen P.C., Gores G.J., LaRusso N.F., et al. Biliary tract cancers. N. Engl. J. Med. 1999, 341:1368-1378.
13. Murphy A. Prostate cancer screening: is human carcinoma antigen a more valid screening test than prostate-specific antigen?. Doris Duke Med. Student's J. 2003-2004, 3:8-9.
14. Iguchi T., Yamashita N., Aishima S., et al. A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. Oncology 2009, 76:293-300.
15. Han S.L., Zhou H.Z., Cheng J., et al. Diagnosis and surgical treatment of intrahepatic hepatolithiasis associated cholangiocarcinoma. Asian J. Surg. 2009, 32:1-6.
16. Stroescu C., Herlea V., Dragnea A., et al. The diagnostic value of cytokeratins and carcinoembryonic antigen immunostaining in differentiating hepatocellular carcinomas from intrahepatic cholangiocarcinomas. J. Gastrointest. Liver Dis. 2006, 15:9-14.
17. Patel A.H., Harnois D.M., Klee G.G., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 2000, 95:204-207.
18. Siqueira E., Schoen R.E., Silverman W., et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest. Endosc. 2002, 56:40-47.
19. Nichols J.C., Gores G.J., LaRusso N.F., et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin. Proc. 1993, 68:874-879.
20. Nakeeb A., Lipsett P.A., Lillemoe K.D., et al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am. J. Surg. 1996, 171:147-152. discussion 152-143.
21. Sasaki M., Nakanuma Y. Expression of mucin core protein of mammary type in primary liver cancer. Hepatology 1994, 20:1192-1197.
22. Tamada S., Goto M., Nomoto M., et al. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol. Int. 2002, 52:713-723.